anoth quarter growth strateg flexibl confirm
wednesday morn april abbott report first-quart earn view
continu recent strong trend seen compani importantli
noth discuss caus us question thesi thesi base
revenu growth top group expect
organ fxn basi first quarter earn growth
doubl digit even face difficult fx environ addit invest
made key product line freestyl libr alin mitraclip name slew
new product opportun varieti segment import de-lever
give compani strateg flexibl reflect guidanc
last point net leverag today stand time build-up cash
solid ebitda expect move closer timeswel
think appropri busi manag commentari nearli
dismiss sort heard last quarter commentari clearli indic
enthusiasm complet strateg flexibl
suggest anyth larg brew believ continu paydown debt
lack desir larg scale repurchas suggest compani aggress
pursu right strateg financi transact appear
model use suggest build-up cash modest interest made
believ wind realiti manag team investor
satisfi notabl non-product-specif commentari call uber-
bullish heard ceo mile white state devic industri
cite rise project growth rate across space driven new product strong
pipelin good volum
thu look forward next month believ end-market demand
remain robust across segment margin expans play pipelin
new product launch continu gain traction back substanti invest
cash flow creat accret opportun believ support current
multipl time forward ep compar three-year averag
time room upsid result number lever compani avail
return equiti ttm
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
strong cash flow abbott gone signific de-lever phase throughout debt/ebitda ratio
finish year time billion debt repurchas throughout year anoth million repaid
first quarter get compani someth could time year-end manag declar
freedom strateg standpoint whatev want suspect drum beat loudli sort deal
later year dividend alreadi rais comfort target zone percent net incom
manag continu dissuad investor call assum larger organ share repurchas
cash reserv model simpli expand
med tech multipl remain premium manag commentari nondescript believ manag
continu hunt potenti asset pond specif continu believ opportun within
establish pharmaceut report solid except growth recent within medic technolog
piec busi strong perhap hole fill attract asset add portfolio
manag histor savvi acquir pick asset face short-term pressur
attract portfolio synergist busi segment though expect compani remain patient
wait right assetand abbott strong intern product launch invest support continu strong
performancew expect manag continu face capit alloc question investor throughout year
eventu deploy leverag drive broader invest thesi
medic technolog industri commentari manag provid except bullish outlook medic devic
landscap abbott-specif segment sector broadli ceo mile white suggest growth continu
rapid pace acceler abbott ceo sector see sign slowdown note
abbott medic devic segment total sale constant currenc quarter
model organ sale growth high-single-digit rang see upsid estim product launch gain
reimburs approv later year
industri growth outlook driven new product launch strong product pipelin improv
util add valu marketplac consist trend last sever year led
multi-year industri bull market said year-to-d medic technolog return ihi medic devic etf
outperform overal healthcar return xlv healthcar etf under-perform return
jone return continu believ underli fundament sector remain strong
drive continu growth sever year come
diabet diabet remain one highlight abbott post anoth strong quarter global sale million
organ led continu adopt abbott freestyl libr fgm system libr highlight first quarter
includ global sale million year-over-year expand user base nearli million global user
million last quarter pharmaci coverag live unit state type type
manag reiter expect continu growth diabet care make headway global
multibillion-dollar cgm market launch next-gen fgm system capabl support long-term growth
continu think remain signific opportun cgm player million insulin-us diabet
unit state alon expect continu momentum libr result organ growth full-year diabet
libr remind libr similar function origin libr add option real-tim alarm
high/low glucos level call manag confirm abbott file fda approv libr icgm
design expect stop short provid timelin expect approv launch
typic turnaround assum approv expect chang price note
compani expect see signific uptak follow approv libr design alarm-fre
devic around sale market effort focus far libr launch germani
solid respons
though initi european trial meet requir icgm manag remain confid libr
meet qualiti accuraci requir icgm design base result domest trial
advantag icgm would allow abbott use less stringent clearanc pathway futur libr
product oppos pma pathway allow quickli launch next-gen system unit state
compani referenc next-gener libr devic call time expect focu
improv form factor eas use patient
suppli chain invest abbott continu heavili invest manufactur capac libr sensor
expect throughput meaning expand second half user growth impress
freestyl libr continu suppli constrain expect somewhat imped sale growth
mitraclip/structur heart first-quart structur heart sale grew organ line manag
expect led continu momentum mitraclip sale mitraclip fda approv expand
label cover treatment secondari mitral regurgit mr march abbott need wait reimburs
approv product sale potenti acceler first-quart call manag alreadi file
reimburs provid firm timelin approv note prior approv taken six nine
month impli late approv given overwhelmingli posit data coapt trial would
surpris reimburs came quicker end timelin conserv model meaning sale
acceler get detail reimburs approv overal remain posit durabl
mitraclip sale abbott make headway larg undertr mr opportun expect coapt trial help
increas surgeon convers util product
pipelin first-quart call manag reiter timelin sever pipelin product expect
support long-term growth structur heart busi transcathet mitral valv replac abbot file
ce mark approv tendyn system continu expect intern launch end
portico compani tavr valv undergo pivot trial expect receiv approval/launch
first half lastli abbott plan start pivot trial triclip treatment leaki tricuspid valv
come month manag believ market triclip patient unit state roughli
one-third patient elig mitraclip
neuromodul first-quart world-wide sale constant currenc quarter sale
compani continu struggl right-siz grow sale organ declin well market growth
manag believ remain double-digit rang
sale relationship invest import driver growth industri believ also
someth compani address note given time hire trial implant perman implant
rep may requir long month becom fulli product notabl compani also materi next-
gener product launch indic expans sinc launch burst drg platform though discuss two new
system updat expect launch year-end earli said like increment updat
focus eas use batteri life abbott doubl invest sinc acquir busi two year ago
time drive new product indic expans meantim expect segment lag behind
diagnost organ fxn subseg growth rate within diagnost bit sloppi compar
expect intern point care molecular declin significantli tough comp think
much caus concern given biggest growth driver alin drive share win team remain
confid growth engin move forward
relat alin strength product roll-out led core lab growth manag note driven
primarili alin launch europ far roll-out seen solid custom retent share win
alin win two-third time competit bid first quarter complet win closer
last month part think equat share gain low singl digit annual basi win rate
move forward next two three quarter team intend round core menu approv requir
acceler adopt mean alin like domest driver revenu beyond menu
domest larg complet year-end follow team deploy addit resourc roll-out
final far influenza season concern manag told us tough comp end million
headwind revenu compar guidanc impli million million headwind season
larg behind us team note inventori distributor channel seem normal level help
eas fear lower sale enter flu season
guidanc manag reiter sale guidanc expect continu rang organ
constant-curr growth similar full year organ sale growth support continuing/acceler
momentum sever key busi segment second quarter team expect sale growth approxim
organ fxn basi busi line manag expect midsingle-digit growth establish pharmaceut
mid- high-single-digit key emerg market midsingle-digit growth nutrit midsingle-digit growth diagnost
mid- high-single-digit legaci diagnost low- midsingle-digit rapid diagnost high-single-digit growth
medic devic support double-digit growth sever busi segment view guidanc achiev
beatabl potenti upsid driver stem new product introduct indic expansionsnam
mitraclip libr alin platform
updat model follow quarterli result manag guidanc
sale maintain sale estim billion reflect organ fxn growth report
growth
earn increas earn per share estim account slight beat
first quarter
sale increas sale estim billion reflect organ fxn growth
earn slightli increas earn per share estim impli year-over-year
growth
